UroVysion FISH for Bladder Cancer

MOL.CS.108.A
v2.0.2020

Procedures addressed

The inclusion of any procedure code in this table does not imply that the code is under management or requires prior authorization. Refer to the specific Health Plan’s procedure code list for management requirements.

<table>
<thead>
<tr>
<th>Procedures addressed by this guideline</th>
<th>Procedure codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>FISH Analysis for Bladder Cancer (UroVysion), Manual</td>
<td>88120</td>
</tr>
<tr>
<td>FISH Analysis for Bladder Cancer (UroVysion), Computer-Assisted</td>
<td>88121</td>
</tr>
</tbody>
</table>

What is UroVysion FISH testing for bladder cancer

Definition

UroVysion™ was developed to be used with current standard diagnostic tools to aid in initial diagnosis of bladder cancer and monitoring for tumor recurrence in previously diagnosed patients.¹

- Bladder cancer is one of the most common types of cancer in the U.S., especially among men. Approximately 79,370 new cases of bladder cancer are projected for 2019 (61,700 in men and 17,670 in women).² Older individuals (median age, 65 years) are most often affected.

- Bladder cancer is categorized as non-muscle invasive disease (NMID) or muscle invasive disease (MID).³ The majority (≈80%) of bladder cancers are NMID.⁴

- Urothelial carcinoma (UC) accounts for most cases of bladder cancer.¹³
  - Most cases of UC are low-grade and easily treated.¹
  - However, UC has a high risk of recurrence (70%), and patients must be monitored for several years after treatment.¹

- Diagnostic monitoring usually consists of regular testing of cells in the urine (cytology).³⁵ UroVysion FISH (fluorescence in situ hybridization) testing is an alternative to cytology.¹⁵
Test information

- UroVysion is a multicolor FISH assay that detects aneuploidy of chromosomes 3, 7 or 17 and loss of the 9p21 chromosomal region, abnormalities often found in UC patients.\(^1\)
- Cytology is the standard procedure for diagnosing and monitoring of UC. UroVysion testing can be performed if the cytology returns negative or atypical results.\(^{1,3,5}\)
- One study showed UroVysion testing to have 85% sensitivity for low-grade UC, and nearly 100% sensitivity for the more rare but serious high-grade UC.\(^1\)

Guidelines and evidence

- The UroVysion testing kit is FDA approved,\(^6\) but reviews and guidelines call for additional study before its clinical use becomes standard procedure.\(^5\)
- The National Comprehensive Cancer Network (NCCN, 2019)\(^3\) stated the following in regard to surveillance of patients with a history of UC:
  - “Urine molecular tests for urothelial tumor markers are now available. Many of these tests have a better sensitivity for detecting bladder cancer than urinary cytology, but specificity is lower. Considering this, evaluation of urinary urothelial tumor markers may be considered during surveillance of high-risk non– muscle-invasive bladder cancer. However, it remains unclear whether these tests offer additional information that is useful for detection and management of non– muscle-invasive bladder tumors. Therefore, the panel considers this to be a category 2B recommendation.”
- The American Urological Association and the Society of Urologic Oncology (AUA, 2016)\(^7\) recently published clinical practice guidelines regarding microscopic hematuria and the management of non-muscle invasive bladder cancer (NMIB). For urinary markers utilized after diagnosis of bladder cancer, they state the following:
  - “In surveillance of NMIC, a clinician should not use urinary biomarkers in place of cystoscopic evaluation (Strong Recommendation; Evidence Strength: Grade B)”
  - “In a patient with a history of low-risk cancer and a normal cystoscopy, a clinician should not routinely use a urinary biomarker or cytology during surveillance. (Expert Opinion)”
  - “In a patient with NMIBC, a clinician may use biomarkers to assess response to intravesical BCG (UroVysion FISH) and adjudicate equivocal cytology (UroVysion FISH and ImmunoCyt). (Expert Opinion)”
- The National Institute for Health and Care Excellence (NICE, 2015)\(^8\) published a guideline regarding the diagnosis and management of bladder cancer. They stated that urinary biomarker tests (such as UroVysion using FISH, ImmunoCyt or a
nuclear matrix protein 22 (NMP22) test may be used for the diagnosis of individuals with suspected bladder cancer.

- The American Urological Association (AUA, 2012)\(^9\) stated the following regarding the management of asymptomatic microhematuria:
  - “The use of urine cytology and urine markers (NMP22, BTA-stat, and UroVysion FISH) is NOT recommended as a part of routine evaluation of the asymptomatic microhematuria patient. (Recommendation: Evidence Strength C).”

- Literature Review
  - A systematic review of UroVysion was conducted by the Agency for Healthcare Research and Quality (AHRQ).\(^10\) Based on 11 studies that were reviewed, the following were noted by authors:
    - Diagnostic testing:
      - The sensitivity of Urovysion to detect bladder cancer among undiagnosed patients with clinical signs and symptoms was 63% (95% CI, 50% to 75%) and specificity was 87% (95% CI, 79% to 93%).
      - The positive likelihood ratio was 5.02 (95% CI 2.93 to 8.60) (moderate increase in the likelihood of disease). The negative likelihood ratio was 0.42 (95% CI 0.30 to 0.59) (small decrease in likelihood of disease).
    - Surveillance testing:
      - For individuals being monitored for cancer recurrence the sensitivity was 55% (95% CI, 36% to 72%; 7 studies) and specificity was 80% (95% CI, 66% to 89%; 6 studies).
      - For evaluation of symptoms, sensitivity was 73% (95% CI, 50% to 88%), based on two studies.
      - The sensitivity of the test increased with higher tumor stage and grade.
  - A number of peer-reviewed studies that evaluate the analytical validity, clinical validity, and clinical utility of the UroVysion test are available.\(^11-18\) These studies demonstrate the potential for the assay to help detect bladder cancer. Limitations were noted including small sample size, lack of reporting of precision estimates, and different reference standards for confirming disease.

**Criteria**

- Previous Testing:
  - No repeat UroVysion\(^\circledR\) testing on the same sample when a result was successfully obtained, AND

- Diagnosis
UroVysion is not indicated for the routine evaluation of hematuria or microhematuria and will not be reimbursed when billed with an ICD10 code in the R31 Hematuria range. Exceptions may be made for uncertain or equivocal results on standard diagnostic assessments, such as cytology, OR

- Surveillance
  - UroVysion is indicated when the individual has a personal history of bladder cancer defined by ICD10 code of Z85.51 (Personal history of malignant neoplasm of bladder) or C67.0-C67.9 (Malignant neoplasm of the bladder, range), AND
  - The member is being monitored for cancer recurrence, AND
    - Member had been diagnosed with low grade bladder cancer and the results of cytology are equivocal, or
    - Member had been diagnosed with high grade bladder cancer and the results of cytology are negative or equivocal, AND

- Rendering laboratory is a qualified provider of service per the Health Plan policy

Billing and reimbursement considerations

Because there are test specific procedure codes available for billing, non-specific procedure codes or any procedure codes that do not accurately describe the test methodology performed are not eligible for reimbursement. For example, 88271 is not a reimbursable code for this test.

References


